This trial is testing a new drug to see if it's effective and safe for people with a disease that causes inflammation in the arteries.
1 Primary · 10 Secondary · Reporting Duration: 52 weeks
Experimental Treatment
Non-Treatment Group
349 Total Participants · 3 Treatment Groups
Primary Treatment: Secukinumab 300 mg · Has Placebo Group · Phase 3
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: